tradingkey.logo

electroCore, Inc.

ECOR
查看詳細走勢圖
4.600USD
+0.180+4.07%
收盤 12/19, 16:00美東報價延遲15分鐘
35.12M總市值
虧損本益比TTM

electroCore, Inc.

4.600
+0.180+4.07%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+4.07%

5天

-3.16%

1月

+0.22%

6月

-10.33%

今年開始到現在

-71.62%

1年

-69.88%

查看詳細走勢圖

TradingKey electroCore, Inc.股票評分

單位: USD 更新時間: 2025-12-19

操作建議

electroCore, Inc.當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名107/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價21.08。中期看,股價處於平穩狀態。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

electroCore, Inc.評分

相關信息

行業排名
107 / 208
全市場排名
245 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 5 分析師
買入
評級
21.080
目標均價
+330.20%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

electroCore, Inc.亮點

亮點風險
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
業績高增長
公司營業收入穩步增長,連續3年增長193.09%
業績增長期
公司處於發展階段,最新年度總收入25.18M美元
估值合理
公司最新PE估值-2.70,處於3年歷史合理位
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉233.47K股
活躍度增加
近期活躍度增加,過去20天平均換手率0.69

electroCore, Inc.新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

electroCore, Inc.簡介

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
公司代碼ECOR
公司electroCore, Inc.
CEOGoldberger (Daniel S)
網址https://www.electrocore.com/

常見問題

electroCore, Inc.(ECOR)的當前股價是多少?

electroCore, Inc.(ECOR)的當前股價是 4.600。

electroCore, Inc. 的股票代碼是什麼?

electroCore, Inc.的股票代碼是ECOR。

electroCore, Inc.股票的52週最高點是多少?

electroCore, Inc.股票的52週最高點是19.490。

electroCore, Inc.股票的52週最低點是多少?

electroCore, Inc.股票的52週最低點是4.160。

electroCore, Inc.的市值是多少?

electroCore, Inc.的市值是35.12M。

electroCore, Inc.的淨利潤是多少?

electroCore, Inc.的淨利潤為-11.89M。

現在electroCore, Inc.(ECOR)的股票是買入、持有還是賣出?

根據分析師評級,electroCore, Inc.(ECOR)的總體評級為買入,目標價格為21.080。

electroCore, Inc.(ECOR)股票的每股收益(EPS TTM)是多少

electroCore, Inc.(ECOR)股票的每股收益(EPS TTM)是-1.704。
KeyAI